Skip to main content

Table 2 TNF-α and IL-10 production in unchallenged PBMCs incubated with oligosaccharide fractions

From: In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation

 

TNF- α (pg/ml)

  

IL-10 (pg/ml)

  

Incubation

Point estimate

Lower bound

Upper bound

Point estimate

Lower bound

Upper bound

Blank controls

12.6

9.8

15.7

187.2

156.2

222.5

GOS 0.5%

19.7 *

16.5

23.3

183.1

152.8

217.7

GOS 1.0%

24.9 *

21.1

29.3

184.2

153.5

219.2

GOS 2.0%

35.5 * #

30.2

41.6

179.8

149.6

214.2

GOS/FOS 0.5%

30.2 *

25.7

35.4

185.5

154.8

221.4

GOS/FOS 1.0%

63.4 * #

54.1

74.2

190.2

160.0

225.7

GOS/FOS 2.0%

127.5 * #

108.6

149.5

186.0

154.5

221.4

GOS/FOS/AOS 0.5%

73.6 *

62.9

86.4

205.2

173.8

242.5

GOS/FOS/AOS 1.0%

133.5 * #

113.7

156.6

214.2

181.6

252.4

GOS/FOS/AOS 2.0%

61.4 * #

52.4

72.2

186.8

157.3

221.0

  1. Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible Intervals for unchallenged PBMCs incubated with oligosaccharide fractions (including blank controls). Significant differences between oligosaccharide fractions and blank controls are marked with an asterisk (*) Significant dose-dependent differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a hash (#).